This article was originally published in Pharmaceutical Approvals Monthly
FDA staff who participated in the review of Novartis’ ceritinib for ALK-positive non-small cell lung cancer.
You may also be interested in...
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.